Hit the target - IL-6 in rare neuroimmunological conditions

Join Our Expert:

The IL-6 signaling pathway is well recognised as a central driver in rare CNS autoimmune conditions and has opened a new therapeutic chapter. This meeting will explore the multifaceted role of IL-6—a pleiotropic cytokine that not only fuels inflammation but also compromises the blood-brain barrier and promotes the survival of pathogenic plasmablasts through upstream mechanisms. As we look toward the future of rare disease management, we will evaluate the clinical value of IL-6 inhibition across a spectrum of disorders, including NMOSD, MOGAD, and Autoimmune Encephalitis.

The clinical expert will discuss how targeting this specific "cytokine hub" can reduce relapse risk, manage long-term disability with an acceptable long-term safety and tolerability profile and convenient administration.

CNS, Central Nervous System; IL-6, Interleukin-6; MOGAD, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease; NMOSD, Neuromyelitis Optica Spectrum Disorder

This Roche-sponsored event is intended for HCPs and members of the scientific community and is not intended for physicians practising in the United States (US). Roche proactively tries to ensure medical education is as widely accessible as possible for HCPs all over the world. This event is organised and funded by Roche. The content of this event is owned by: F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland. © 2026 F. Hoffmann-La Roche Ltd. All trademarks mentioned herein are protected by law. www.roche.com.